Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

The Christie NHS Foundation Trust

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: -

Established: 2007-01-01

Employees: -

Market Cap: -

Website: http://www.christie.nhs.uk/

Clinical Trials

TIL Therapy in Metastatic Melanoma and IL2 Dose Assessment

Phase 2

Terminated

Conditions: Metastatic Melanoma

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Genetic: Tumour Infiltrating Lymphocytes
Drug: Interleukin-2

First Posted Date: 2013-11-26

Last Posted Date: 2023-04-20

Lead Sponsor: The Christie NHS Foundation Trust

Target Recruit Count: 2

Registration Number: NCT01995344

Locations: 🇬🇧
The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom

MRI in Pre-operative Radiotherapy for Soft Tissue Sarcoma: MISTS Study

Not Applicable

Completed

Conditions: Sarcoma

Interventions: Device: MRI scanning

First Posted Date: 2013-10-08

Last Posted Date: 2017-04-26

Lead Sponsor: The Christie NHS Foundation Trust

Target Recruit Count: 15

Registration Number: NCT01956019

Locations: 🇬🇧
The Christie NHS Foundation Trust, Manchester, United Kingdom

NIMRAD (A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab)

Phase 3

Completed

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Nimorazole
Radiation: Radiotherapy

First Posted Date: 2013-09-25

Last Posted Date: 2021-10-19

Lead Sponsor: The Christie NHS Foundation Trust

Target Recruit Count: 338

Registration Number: NCT01950689

Locations: 🇬🇧
Cheltenham General Hospital, Cheltenham, Gloucestershire, United Kingdom
🇬🇧
Clatterbridge Centre for Oncology, Bebington, Merseyside, United Kingdom
🇬🇧
St James' Hospital, Leeds, West Yorkshire, United Kingdom

and more 18 locations

Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers

Phase 3

Completed

Conditions: Ampullary Cancer
Cholangiocarcinoma
Biliary Tract Cancer
Gallbladder Cancer

Interventions: Other: Active Symptom Control
Drug: L-folinic acid
Drug: 5 FU
Drug: Oxaliplatin

First Posted Date: 2013-08-20

Last Posted Date: 2020-01-28

Lead Sponsor: The Christie NHS Foundation Trust

Target Recruit Count: 162

Registration Number: NCT01926236

Locations: 🇬🇧
Queen Elizabeth Hospital, Birmingham, United Kingdom
🇬🇧
Bristol Haematology & Oncology Centre, Bristol, United Kingdom
🇬🇧
North Cumbria University Hospitals, Carlisle, United Kingdom

and more 14 locations

Development of a Biomarker Directed Strategy to Ameliorate Common Toxicities From Conventional Chemotherapy

Suspended

Conditions: Sarcoma
Lymphoma

Interventions: Procedure: Biomarker and health economics

First Posted Date: 2013-08-14

Last Posted Date: 2015-02-04

Lead Sponsor: The Christie NHS Foundation Trust

Target Recruit Count: 50

Registration Number: NCT01921998

Locations: 🇬🇧
The Christie NHS Foundation Trust, Manchester, United Kingdom

The Use of Rectal Balloons in Radical Pelvic Radiotherapy - a Feasibility Study

Not Applicable

Conditions: Prostate Cancer

Interventions: Device: Endorectal Balloon insertion

First Posted Date: 2013-04-30

Last Posted Date: 2014-07-30

Lead Sponsor: The Christie NHS Foundation Trust

Target Recruit Count: 10

Registration Number: NCT01842750

Locations: 🇬🇧
Christie Hospital NHS Foundation Trust, Manchester, United Kingdom

A Phase I Study of CD19 Specific T Cells in CD19 Positive Malignancy

Phase 1

Terminated

Conditions: CD19 Positive Non-Hodgkin Lymphoma

Interventions: Genetic: aCD19z cells, IL2, pre conditioning Cyclophosphamide & Fludarabine

First Posted Date: 2011-12-16

Last Posted Date: 2023-04-19

Lead Sponsor: The Christie NHS Foundation Trust

Target Recruit Count: 17

Registration Number: NCT01493453

Locations: 🇬🇧
The Christie NHS Foundation Trust, Manchester, United Kingdom

Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma

Phase 2

Completed

Conditions: Follicular Lymphoma

Interventions: Drug: 90Y Ibritumomab tiuxetan
Drug: Rituximab

First Posted Date: 2011-12-16

Last Posted Date: 2019-10-15

Lead Sponsor: The Christie NHS Foundation Trust

Target Recruit Count: 76

Registration Number: NCT01493479

Locations: 🇫🇷
Centre Hospitalier Universitaire de Lille, Lille, France
🇫🇷
Centre Hospitalier Universitaire de Nantes, Nantes, France
🇫🇷
Centre Henri Becquerel, Rouen, France

and more 4 locations

Radiotherapy & Olaparib in COmbination for Carcinoma of the Oesophagus

Phase 1

Conditions: Carcinoma of the Oesophagus

Interventions: Drug: Olaparib
Radiation: Radical external beam radiotherapy, 50Gy in 25 fractions

First Posted Date: 2011-10-27

Last Posted Date: 2013-08-19

Lead Sponsor: The Christie NHS Foundation Trust

Target Recruit Count: 36

Registration Number: NCT01460888

Locations: 🇬🇧
The Christie NHS Foundation Trust, Manchester, United Kingdom
🇬🇧
Southampton General Hospital, Southampton, United Kingdom

Measurement of Gemcitabine Metabolites in Blood and Urine as Predictors of Response to GemX Bladder Radiotherapy

Not Applicable

Completed

Conditions: Bladder Cancer

Interventions: Other: Sample Collection

First Posted Date: 2011-04-27

Last Posted Date: 2021-08-13

Lead Sponsor: The Christie NHS Foundation Trust

Target Recruit Count: 50

Registration Number: NCT01343121

Locations: 🇬🇧
The Christie NHS Foundation Trust, Manchester, Gtr Manchester, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy